Zim Laboratories Ltd. (IN:ZIMLAB)
:ZIMLAB
Want to see IN:ZIMLAB full AI Analyst Report?
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹126.95
Previous CloseN/A
Volume52.11K
Average Volume (3M)6.28K
Market Cap
₹6.08B
Enterprise Value₹6.30B
Total Cash (Recent Filing)₹50.12M
Total Debt (Recent Filing)₹1.23B
Price to Earnings (P/E)96.4
Beta1.15
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.35
Shares Outstanding53,549,038
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)1.00
Price to Sales (P/S)0.79
P/FCF Ratio-39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Drug‑delivery ProductsZim’s focus on differentiated oral formats (odts/strips) is a durable competitive advantage: these specialized formulations face fewer generic competitors, can command better margins, and support niche market positioning. Over 2–6 months this enables stable product-level pricing and partner interest for registrations and licensing.
Multiple Revenue Streams (branded, Export, Contract)A diversified monetization mix reduces single-market exposure and supports steady cash inflows: branded franchises, export registrations, and contract manufacturing provide different growth levers. Structurally this spreads execution risk and offers repeatable pathways to scale across markets and partners.
Balance Sheet Supported By Rising Equity And Moderate LeverageRising equity and moderate debt give Zim financial flexibility to fund registrations, capex, or strategic partnerships without excessive solvency risk. Over months this improves ability to invest in manufacturing capacity or product registrations while maintaining access to capital if needed.
Bears Say
Negative And Volatile Free Cash FlowReturn to negative FCF and prior volatility constrains internal funding for growth, R&D, and registrations. Persistent negative FCF raises reliance on external financing or equity, increases financing risk, and can limit durability of strategic investments over the next several quarters.
Recent Weakening ProfitabilityMarked decline in net income and operating profit indicates margin pressure and lower earnings quality. If structural (costs, pricing, mix) these trends can erode reinvestment capacity and returns on capital, limiting the company’s ability to fund product development or expand margins sustainably.
Inconsistent Revenue Growth TrendIrregular top‑line trajectory hampers scale benefits and planning: inconsistent growth complicates capacity utilization and forecasting, undermining pricing power and making margin recovery harder. Structural inconsistency increases execution risk for multi‑quarter strategic initiatives.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹126.95 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹6.08B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on May 19, 2026. The company reported ₹0.76 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.76.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 53,549,038 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of ₹0.76 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZIM specializes in providing technology-driven drug delivery solutions and exclusive, non-infringing manufacturing processes for generic pharmaceuticals. These offerings span semi-finished and finished product categories, encompassing forms like granules, pellets, taste-masked powders, suspensions, tablets, capsules, and oral thin films. Their extensive product range caters to various therapeutic areas, including urology, gastroenterology, cardiology, and anticoagulation, alongside antibiotics, anti-infectives, NSAIDs/pain management, and vitamins and supplements.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Kilitch Drugs (India) Limited
―
Medico Remedies Ltd.
―
Valiant Laboratories Ltd.
―